United States: Pleading Direct Patent Infringement In ANDA Cases Upon Information And Belief

December 5, 2015, saw the abrogation of Federal Rule of Civil Procedure 84 and Form 18, the sample complaint for direct patent infringement. Since that date, courts have uniformly applied the pleading standard set forth in two less recent Supreme Court cases to complaints alleging direct patent infringement. Under this standard, the complaint must provide sufficient factual allegations "to state a claim for relief that is plausible on its face." Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is plausible when "the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." Ashcroft v. Iqbal, 556 U.S. 662, 678(2009). "Determining whether a complaint states a plausible claim for relief will . . . be a context-specific task that requires the reviewing court to draw on its judicial experience and common sense." Id., 556 U.S. at 679.

In cases brought pursuant to the Hatch Waxman Act, the submission to the FDA of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification of patent invalidity or non-infringement is the "artificial" act of infringement giving rise to a cause of action. 35 U.S.C. § 271(e)(2). The ANDA filer is required to give notice of the Paragraph IV certification filing to the patentee, who then has 45 days in which to bring suit in order to receive a 30-month stay of ANDA approval pending the litigation outcome. 21 U.S.C. § 355(j)(5)(B)(iii). Prior to the receipt of a Paragraph IV notice, a patentee is generally in the dark as to the existence, composition, and properties of the ANDA filer's proposed drug product. Furthermore, the Paragraph IV certification notice letter does not always provide all of the details of the ANDA product, particularly if it does not provide any substantive non-infringement position. During the 45-day period, the patentee can obtain additional information regarding the ANDA product, usually under the terms of an Offer of Confidential Access (OCA) that restrict access of the confidential ANDA information and may forbid any mention of such information in any publicly available pleading. In this post-Rule 84 era, and under the Twombly and Iqbal standards, the patentee must then balance the need to allege sufficient facts to support a plausible claim for patent infringement with its lack of access to information or its potential obligation to keep certain details regarding the ANDA product confidential.

Fortunately for the Hatch Waxman Act plaintiff, the Federal Circuit has acknowledged, albeit with respect to Form 18, that "[a] defendant cannot shield itself from a complaint . . . by operating in such secrecy that the filing of a complaint itself is impossible." K-Tech Telecommunications, Inc. v. Time Warner Cable, Inc., 714 F.3d 1277, 1286 (Fed. Cir. 2013). Furthermore, the plausibility standard is a flexible one. Iqbal, 556 U.S. at 679; see also DermaFocus LLC v. Ulthera, Inc., No. 15-654-SLR, 2016 BL 261077 (D. Del. Aug. 11, 2016) (finding that the plaintiff had given the defendant reasonable notice of a plausible claim for direct infringement using certain, more limited information where "it is not apparent to the court whether the information demanded by the defendant is in the public domain and, therefore, reasonably available to plaintiff").

Where the information needed to eventually prove infringement either rests solely in the hands of the accused infringer or is subject to an obligation of confidentiality, courts generally allow plaintiffs to allege facts "upon information and belief." See Fed. R. Civ. P. 11(b)(3). For example, in Takeda Pharmaceuticals U.S.A., Inc. v. West-Ward Pharmaceutical Corp., the second amended complaint presented a claim of induced infringement based on defendant Hikma's "active encouragement of third-party infringement, including Mitigare sales representatives' statements telling healthcare providers to prescribe Mitigare for the unapproved indications covered by Takeda's patents . . . and its distribution of a sales aid which explicitly references [guidelines] that recommend Takeda's patented methods." No. 14-1268-SLR, 2016 BL 414733 (D. Del. Dec. 14, 2016). Hikma argued that Takeda provided no details as to the identity of the persons involved in the conversations or when such conversations took place, and thus dismissal would be appropriate given the Twombly and Iqbal standards. However, "given that Hikma would be the actual source of the requisite factual information, the court conclude[d] that the proposed second complaint contain[ed] sufficiently detailed allegations (1) to plausibly give rise to a claim for inducement of patent infringement, and (2) to give Hikma fair notice of such claim." Id.

Similarly, the court in Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc. held that the allegation that "[o]n information and belief, Teva has or will have knowledge [sic] that if it were to [make and sell its proposed ANDA product] during the proposed shelf life of the product, such activities would result in the sale and/or use of an infringing article" was sufficient to withstand a motion to dismiss. No. 14-874-SLR, 2015 BL 210448 (D. Del. Jul. 1, 2015). Merck grounded its claim of infringement on the theory that the substance present in Teva's ANDA product would convert, during the shelf life of the product, to the claimed substance. Although Merck did not expressly identify and provide details of its conversion theory in its complaint, the court found Merck's allegation plausible, noting that "to rule in favor of Teva on this issue, the court would have to credit Teva's interpretation of Merck's theory over the language of the complaint itself." Id. (also declining "to engage in a fact finding analysis regarding the merits of Merck's theory of liability at the pleadings stage"). Beware, however, that conclusory allegations "upon information and belief" may not suffice in some circumstances. E.g., McDermott v. Clondalkin Grp., Inc., 649 F. App'x 263, 267-268 (3d Cir. 2016) (boilerplate and conclusory allegations unaccompanied by factual allegations that make the claim plausible will not suffice); TeleSign Corp. v. Twilio, Inc., No. 16-2106, 2016 BL 297262 (C.D. Cal. Aug. 3, 2016) (allegation that "[o]n information and belief, Twilio is making, using, selling, offering to sell and/or importing technology similar to the above-mentioned products and services but not known to Telesign" and such related technology "is also within the scope of the 'Accused Technologies'" is "clearly deficient").

In an ANDA case, the plaintiff can generally begin by alleging public facts that can be gleaned from the Paragraph IV notice letter (which is not confidential), the portions of its own product labeling that the ANDA filer must copy, and the fact that ANDA products are generally touted by the ANDA filer as pharmaceutically equivalent, bioequivalent, and therefore therapeutically equivalent to the branded product. For Orange Book-listed patents that have relatively straight-forward claims directed to the active pharmaceutical ingredient or methods of treatment, those factual allegations may well suffice for direct infringement. For other patents, such as for example those directed to particular formulations or polymorphs, the plaintiff should be able to allege confidential or missing information that is likely to have evidentiary support after the discovery process "upon information and belief" and withstand a motion to dismiss.

Originally printed in  BNA's Pharmaceutical Law & Industry Report on April 14, 2017.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

15 Nov 2017, Conference, London, UK

Finnegan partner Leythem Wall will consider European claim drafting strategy and will lead the Chemical Workshop during a two-day course, hosted by Management Forum.

15 Nov 2017, Seminar, Amsterdam, Netherlands

Finnegan partner Anthony Tridico will lead Forum Institute for Management’s course comparing patent law in the United States and Europe.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.